312753-75-6Relevant academic research and scientific papers
Scalable ruthenium-catalyzed asymmetric synthesis of a key intermediate for the β2-adrenergic receptor agonist
Komiyama, Masato,Itoh, Takahiro,Takeyasu, Takumi
, p. 315 - 319 (2015)
An enantioselective and robust synthetic process to obtain a useful intermediate for the β2-adrenergic receptor agonist is described. Asymmetric transfer hydrogenation of ketone 1c by (S,S)-3b (Ms-DENEB) afforded chiral alcohol 2c in 71% isolated yield and 99% ee. The deprotection completed the synthesis of (R)-5 in 41% overall yield from 1b, which is readily commercially available.
COMPOUND HAVING β2 ADRENALINE RECEPTOR AGONIST ACTIVITY AND METHOD FOR PRODUCING INTERMEDIATE THEREOF, AND COMPOUND THEREOF
-
, (2017/01/02)
PROBLEM TO BE SOLVED: To provide a compound which has a β2 adrenaline receptor (adrenoreceptor) agonist activity and a new efficient method for producing the compound. SOLUTION: There is provided: a new method for producing a compound, which is represented by the formula (III) as a pharmaceutical and has adrenoreceptor agonist activity, via a compound represented by the formula (II) from a compound represented by the formula (I); and the compound. (X is a leaving group or an amino group which is substituted with one H or an alkyl group R1 and one H or a protective group P2 of an amino group.) COPYRIGHT: (C)2015,JPOandINPIT
Beta2-adrenoceptor agonists
-
Page/Page column 17, (2008/06/13)
Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
